Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35032429.
- Also identified by DOI 10.1016/j.cell.2021.12.040 and PMC identifier 8712270.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathology, and it remains unclear whether T cells contribute to disease pathology. Here, we combined single-cell transcriptomics and single-cell proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated CD16<sup>+</sup> T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune-complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16<sup>+</sup> T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16<sup>+</sup> T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Increased generation of C3a in severe COVID-19 induced activated CD16<sup>+</sup> cytotoxic T cells. Proportions of activated CD16<sup>+</sup> T cells and plasma levels of complement proteins upstream of C3a were associated with fatal outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.
Medical subject headings
- COVID-19
- Complement Activation
- Proteome
- SARS-CoV-2
- T-Lymphocytes, Cytotoxic
- Transcriptome